ETIOLOGY AND PATHOGENESIS OF HEPATITIS B VIRUS

Authors

  • Xamraqulova Nigora Student, Faculty of General Medicine, Andijan Branch of KokandUniversity
  • Mirzayeva Saidaxon Abdusalomovna Professor, Department of Microbiology, Virology and Immunology, Andijan Branch of Kokand University

Keywords:

Hepatitis B, Hepatitis B virus (HBV), liver cirrhosis, HBsAg, antiviral therapy, vaccination, chronic infection, liver cancer.

Abstract

Hepatitis B is a dangerous infectious liver disease caused by the Hepatitis B virus (HBV), affecting approximately 254 million people worldwide. The disease is transmitted through blood, sexual contact, and mother-to-child transmission. Occurring in both acute and chronic forms, untreated Hepatitis B may lead to liver cirrhosis and liver cancer. Diagnostic methods mainly include testing for HBsAg, HBV DNA, and liver enzyme levels. Chronic Hepatitis B is controlled using antiviral medications such as Tenofovir and Entecavir. The most reliable preventive measure is the three-dose vaccine, which has an effectiveness rate of 95–98%. In Uzbekistan, the Hepatitis B vaccine is included in the national immunization schedule and is mandatory for newborns.

Downloads

Download data is not yet available.

References

. Inomov J.I., Nazarov Sh.E. "Issues of the spread and prevention of hepatitis B in Uzbekistan." Medical Journal, Tashkent, 2021. - pp. 45-52.

2. Mirzayev A.Kh., Kholikov B.T. "Modern methods of treating chronic viral hepatitis." Medical Bulletin of Uzbekistan, 2020. - Issue 3, pp. 28-34.

Rashidova N.S. "Hepatitis B prevention and vaccination effectiveness in newborns." Pediatrics Journal, Tashkent, 2022. - pp. 67-73.O'zbekiston

Ministry of Health of the Republic of Uzbekistan. "State Program for Combating Viral Hepatitis 2017-2021." Tashkent, 2017.

Khasanov A.A., Toshmatov U.R. "The relationship between liver cirrhosis and hepatocellular carcinoma with hepatitis B." Medical Journal of Uzbekistan, 2019. - Issue 2, pp. 14-19.

World Health Organization. "Global Hepatitis Report 2023." Geneva: WHO Press, 2023. - 112 p.

European Association for the Study of the Liver (EASL). "Clinical Practice Guidelines on Hepatitis B Virus Infection." Journal of Hepatology, 2017. Vol. 67, No. 2. - P. 370-398.

Terrault N.A., Lok A.S.F., McMahon B.J. et al. "Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance." Hepatology, 2018. Vol. 67, No. 4. - P. 1560-1599.

Lok A.S.F., Brook M.F. "Chronic Hepatitis B: Update 2009." Hepatology, 2009. Vol. 50, No. 3. - P. 661-662.

Revill P.A., Chisari F.V., Block J.M. et al. "A Global Scientific Strategy to Cure Hepatitis B." Lancet Gastroenterology & Hepatology, 2019. Vol. 4, No. 7. -P. 545-558

Downloads

Published

2026-05-19

How to Cite

Xamraqulova Nigora, & Mirzayeva Saidaxon Abdusalomovna. (2026). ETIOLOGY AND PATHOGENESIS OF HEPATITIS B VIRUS. Journal of Applied Science and Social Science, 16(5), 746–749. Retrieved from https://www.internationaljournal.co.in/index.php/jasass/article/view/4421

Issue

Vol. 16 No. 5 (2026): Journal of Applied Science and Social Science

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in the Journal of Applied Science and Social Science (JASSS) is protected by copyright. Authors retain the copyright to their work, and grant JASSS the right to publish the work under a Creative Commons Attribution License (CC BY). This license allows others to distribute, remix, adapt, and build upon the work, even commercially, as long as they credit the author(s) for the original creation.